May 3, 2018 / 10:54 AM / 20 days ago

BRIEF-Merck Provides Update On Keynote-407 Trial

May 3 (Reuters) - Merck & Co Inc:

* MERCK PROVIDES UPDATE ON KEYNOTE-407 TRIAL

* MERCK - PHASE 3 KEYNOTE-407 TRIAL MET A PRE-SPECIFIED SECONDARY ENDPOINT OF ORR IN AN EARLY COHORT OF PARTICIPANTS AT AN INTERIM ANALYSIS

* MERCK & CO INC - NOW EXPECTS THAT AN ADDITIONAL INTERIM ANALYSIS WILL BE CONDUCTED PRIOR TO ASCO

* MERCK - BASED ON KEYNOTE-407 TRIAL DATA, RECENTLY SUBMITTED A SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO U.S. FDA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below